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The concept of platelets as important players in the process of atherogenesis has become
increasingly accepted due to accumulating experimental and clinical evidence. Despite the
progress in understanding the molecular details of atherosclerosis, particularly by using
animal models, the inflammatory and thrombotic roles of activated platelet s especially
in the human system remain difficult to dissect, as often only the complications of
atherosclerosis, i.e., stroke and myocardial infarction are definable but not the plaque
burden. Platelet indices including platelet count and mean platelet volume (MPV) and
soluble mediators released by activated platelets are associated with atherosclerosis. The
chemokine CXCL4 has multiple atherogenic activities, e.g., altering the differentiation of T
cells and macrophages by inhibiting neutrophil and monocyte apoptosis and by increasing
the uptake of oxLDL and synergizing with CCL5. CCL5 is released and deposited on
endothelium by activated platelets thereby triggering atherogenic monocyte recruitment,
which can be attenuated by blocking the corresponding chemokine receptor CCR5.
Atheroprotective and plaque stabilizing properties are attributed to CXCL12, which plays
an important role in regenerative processes by attracting progenitor cells. Its release
from luminal attached platelets accelerates endothelial healing after injury. Platelet surface
molecules GPIIb/IIIa, GP1bα, P-selectin, JAM-A and the CD40/CD40L dyade are crucially
involved in the interaction with endothelial cells, leukocytes and matrix molecules affecting
atherogenesis. Beyond the effects on the arterial inflammatory infiltrate, platelets affect
cholesterol metabolism by binding, modifying and endocytosing LDL particles via their
scavenger receptors and contribute to the formation of lipid laden macrophages. Current
medical therapies for the prevention of atherosclerotic therapies enable the elucidation of
mechanisms linking platelets to inflammation and atherosclerosis.
Keywords: atheroscleosis, chemokines, adhesion molecules, platelet aggregation inhibitors, platelet count,
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ROLE OF PLATELETS IN ATHEROGENESIS
Despite the increasing knowledge about the intricate pathogen-
esis of atherosclerosis our therapeutic achievements have not
much further evolved since the approval of statins. Various cell
types and numerous mediators have been identified to con-
tribute in exacerbating or resolving atherosclerotic lesions and are
thus principally to be considered as potential targets (Weber and
Noels, 2011). The relevance of platelets for atherogenesis, at least
for the human system, remains controversial and incompletely
understood.
PLATELET INDICES
One of the early studies giving rise to the hypothesis of platelets
as atherogenic factor came from a prospective trial that measured
the platelet count and ADP responsiveness in ∼500 healthy mid-
dle aged men which were followed up over 13 years. Patients
presenting with the highest quartile of circulating platelets had
an increased risk of coronary death, whereas non-fatal coro-
nary events were not associated. Additionally, patients with a
fast and short platelet response to ADP were at higher risk
than patients with a slow response to ADP (Thaulow et al.,
1991). Of the classical Framingham risk factors only smoking
was positively correlated with platelet count and adjustment for
smoking still revealed an association of the platelet count and
fatal coronary heart disease. As atherosclerotic lesion develop-
ment was not monitored, the results can be interpreted in a way
that highly reactive and numerous platelets represent a risk for
a non-resolving platelet thrombus and/or that reactive platelets
lead to an increase in vulnerable plaques. In the ARIC trial
(Atherosclerosis Risk in Communities) however, ∼15,000 coro-
nary healthy patients were followed over 5 years and a high
platelet count was suggestive but not significantly associated with
coronary disease incidence including non-fatal events (Folsom
et al., 1997). Other platelet indices such as mean platelet volume
(MPV) have been reported to represent a measure for platelet
activation. A meta-analysis comprising 24 trials and a total
of ∼6000 patients found MPV to be a cardiovascular risk fac-
tor associated with acute myocardial infarction (AMI), mortality
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following myocardial infarction, and restenosis following coro-
nary angioplasty (Chu et al., 2010). MPV has been reported to be
increased in hypertension, dyslipidemia, and inflammation and
may be reduced by statins (Nadar et al., 2004; Coban and Afacan,
2008).
Lifestyle and nutrition are important factors affecting athero-
genesis and are amenable to behavioral changes improving the
individual prognosis. For example high intake of saturated fat
is believed to be atherogenic, as it correlates positively in most
countries with high cardiovascular mortality. In France the sit-
uation seems to be paradoxical as cardiovascular mortality is
comparatively low despite a high consumption of saturated fats
and equal distribution of traditional risk factors. Platelet inhibi-
tion by alcohol and unspecified ingredients of wine have been
a potential explanation (Renaud and Delorgeril, 1992; Renaud
et al., 1992; Rimm et al., 1999). Resveratrol is such a prominent
candidate and has been promoted to prevent cardiovascular mor-
tality, but lately failed to hold promises (Semba et al., 2014). As
mentioned above, the number of circulating platelets is associated
with cardiovascular events. The type of diet not only influences
cholesterol levels but as well the platelet count. In the Moli-Sany
study ∼15,000 healthy Italians were stratified according to the
type of diet they adhered. A mediterranean diet correlated with
a low platelet count (Bonaccio et al., 2014). The perception of the
platelet count as therapeutic target was picked up by an experi-
mental approach in baboons reducing thrombopoiesis by block-
ing thrombopoietin using antiserum which reduced platelets by
40% and inhibited thrombosis but not hemostasis (Tucker et al.,
2010).
CHEMOKINES AND SOLUBLE IMMUNE MEDIATORS
Platelet activation results in the release of soluble immune mod-
ulators that are stored in α or dense granules or, in the case
of IL-1β, are processed in the cytoplasm. Platelet degranulation
determined by CD63 upregulation correlated with the progres-
sion of the carotid intima-media-thickness (Fateh-Moghadam
et al., 2005).
DENSE GRANULES
Dense granules are packed with small molecules such as
pyrophosphates and nucleotides (Mcnicol and Israels, 1999).
Moreover, proteomics revealed more than 40 proteins including
14-3-3zeta which can be released by activated platelets and was
detectable in human atherosclerotic lesions but not normal
aortic tissue (Hernandez-Ruiz et al., 2007). Dense granule release
contributes crucially to atherothrombosis and atherosclerosis
like remodeling, as HSP3−/− deficient mice that have a defect
in dense granule secretion developed less atherosclerosis (King
et al., 2009).
ALPHA-GRANULES
Platelet mediators affecting inflammation such as chemokines
and growth factors (TGFβ) are kept in α-granules. Some
chemokines such as CXCL4 and CXCL7, are amongst the high-
est expressed proteins in platelets and are detectable in other
cell types only in low amounts under physiologic conditions
(Karshovska et al., 2013).
CXCL7
The role of CXCL7 in atherosclerosis is not well-understood.
From the gene CXCL7 the proteins platelet basic protein,
beta-thromboglobulin and CTAPIII arise by proteolytic cleavage
and are not chemotactic. Only after their release and further N-
terminal shortening they bind the receptors CXCR1 and CXCR2,
thereby prompting neutrophils and endothelial progenitor cells to
migrate (Gleissner, 2012b).
CXCL4
CXCL4 was the first of around 50 members of the chemokine
family to be cloned and discovered in releasates from platelets
(Von Hundelshausen et al., 2007). Physiologic plasma levels of
CXCL4 are much higher than of other chemokines. CXCL4
inhibits the proliferation, apoptosis and primes the differenti-
ation of cell types both of the adaptive and innate immune
system at high (micromolar) concentrations, which disfavors sig-
naling via G protein coupled receptors. In keeping with this,
although the chemokine receptor CXCR3 binds CXCL4, not all
of CXCL4-dependent effects are explicable by CXCR3 signaling.
Therefore, the principle how CXCL4 exerts its effects remains
largely obscure.
In humans, CXCL4 was detected in early and late atheroscle-
rotic lesions of the carotid artery, correlating with the histological
and clinical severity of the disease (Pitsilos et al., 2003). CXCL4
deficiency in wildtype and apoE−/− mice and the transplan-
tation of CXCL4 deficient bone marrow into apoE−/− mice
on diet results in smaller atherosclerotic lesions with reduced
macrophage infiltration (Sachais et al., 2007; Koenen et al., 2009).
In addition, CXCL4 plays a role in T cell-platelet interactions,
which contribute to the pathogenesis of atherosclerosis (Li, 2013).
Co-culture of human platelets with activated CD4(+) T cells
resulted in an increased secretion of IFN-γ by soluble mediators
including CXCL4 and CCL5 as well as direct cell–cell contacts
and skewing toward TH1, TH17, and regulatory T cell phenotypes
(Gerdes et al., 2011). CXCL4 is a potent inhibitor of prolifer-
ation for various cell types including T cells, but surprisingly
stimulated selectively the proliferation of regulatory T cells (Liu
et al., 2005). Moreover, CXCL4 promotes neutrophil and mono-
cyte survival by limiting apoptosis (Scheuerer et al., 2000; Hartwig
et al., 2014) and at the same time alters the monocyte phenotype
into a subtype that neither represents a classical macrophage nor
dendritic cell (Fricke et al., 2004). These findings were corrobo-
rated in the sense that in the absence of M-CSF, CXCL4-induced
macrophages display a distinct transcriptome and this type of
macrophages was suggested to be termed M4 and associate with
atherosclerosis (Gleissner et al., 2010). CD163 was one of the
most prominently downregulated genes by CXCL4 and both
genes correlated inversely in human atherosclerotic plaque mate-
rial (Gleissner et al., 2010; Gleissner, 2012a). CD163 is a scavenger
receptor for haptoglobin-hemoglobin complexes (Hp-Hb) which
plays an important role in the clearance of hemoglobin, thereby
upregulating heme oxygenase-1 (HMOX1) activity. CD163 defi-
cient macrophages did not upregulate HMOX-1 after challenge
with Hp-Hb. Hemoglobin occurs in advanced atherosclerosis and
plaque hemorrhage driving a novel protective macrophage subset
(Mhem), which seems to be the natural counterpart of the M4
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type. In line with these results and the role of iron metabolism
in atherosclerosis, macrophages that display high levels of CD163
and contain intracellular iron are considered atheroprotective
(Boyle et al., 2012; Hopkins, 2013). Controversially, the condi-
tional deletion of HMOX-1 in murine macrophages protected
mice from obesity-induced inflammation and insulin resistance
suggesting an atheroprotective role of HMOX-1 (Jais et al., 2014).
An additional mechanism how CXCL4 might influence
atherogenesis is an enhanced recruitment of lipids to arteries and
macrophages. Already very early studies pointed toward a role
of phagocytosed platelets to the fatty alterations of monocytes
(Chandler and Hand, 1961). More recent experiments found that
oxLDL particles are bound by CXCL4, resulting in enhanced
uptake by macrophages finally leading to foam cell formation
(Nassar et al., 2003).
Lastly, and more speculative as the role of IL-17 in
atherosclerosis is controversially discussed, CXCL4 might influ-
ence atherosclerosis by limiting Th17-dependent inflammatory
processes as CXCL4 was shown to limit Th17 differentiation (Shi
et al., 2014).
CCL5
CCL5 is among the highest expressed chemokines on transcript
and protein level in platelets (Karshovska et al., 2013) and acti-
vates mainly CCR5 and CCR1 receptors. Contact of circulating
platelets, their microparticles or releasates with endothelium leads
to a deposition of CCL5 and other mediators to the endothelial
GAG-decorated surface or vessel lumenmediatingmonocyte acti-
vation and adhesion (Von Hundelshausen et al., 2001). Blocking
CCL5 receptors in the mouse by injecting Met-RANTES reduces
atherosclerosis not only by preventing monocyte recruitment to
the vessel wall, but as well by limiting the number of circulating
inflammatory monocytes (Veillard et al., 2004; Combadiere et al.,
2008).
The expression of the ATP-cassette transporter ABCB6 is
restricted to megakaryocyte-erythrocyte progenitors. Its genetic
deletion accelerates atherosclerosis and is associated with ele-
vated plasma levels of CCL5, an expansion of the platelet count,
increase in MPV, and elevation of activation markers such
as P-selectin, and leukocyte-platelet complexes (Murphy et al.,
2014). A potential therapeutic strategy and proof of principle of
an anti-inflammatory atheroprotective therapy could be the eval-
uation of the CCR5 antagonist maraviroc (UK-427857) that is
already in clinical use as HIV entry blocker and which was shown
in the murine system to reduce atherosclerosis without affecting
lipid levels (Cipriani et al., 2013). As maraviroc is well-tolerable,
a further exploration in the prevention of human atherosclerosis
is warranted.
CXCL4-CCL5 heteromers
We found that CXCL4 increases the propensity of CCL5 to trig-
ger monocyte arrest by synergistic interaction and formation
of CXCL4-CCL5 complexes. Additionally, transfectants express-
ing CCR1 and CCR5 variants demonstrated the importance of
CCR1 and its third external loop for the activity of CXCL4-
CCL5 heteromers (Von Hundelshausen et al., 2005; Kramp et al.,
2013). Modeling of the interface and design of a corresponding
peptide disrupting the interaction partners provided evidence
that the complexes are atherogenic and that injection of the pep-
tide inhibitor prevents in part atherosclerotic lesion formation
(Koenen et al., 2009). A variant of CXCL4 with substitutions of
three amino acids in the C-terminus is expressed by human but
not murine platelets. This variant has low affinity for heparin
and CCL5 and lacks synergistic monocyte adhesion (Sarabi et al.,
2011; Karshovska et al., 2013; Kuo et al., 2013). Moreover, injec-
tion of activated platelets in atherosclerosis-prone mice resulted
in a P-selectin-dependent endothelial deposition of CCL5 and
CXCL4 and increased lesion formation (Huo et al., 2003).
CXCL12
CXCL12 or stromal cell derived factor 1 (SDF-1α) is a vital and
well-studied chemokine, which is expressed by various cell types
and stored in platelet α-granules. As key mediator of regenerative
processes CXCL12 binds and regulates homeostasis, localization
and trafficking of endothelial and smooth muscle progenitor
cells via CXCR4 and CXCR7. Using the regenerative properties
of CXCL12 has been envisioned to be applicable in myocardial
infarction and arterial injury (Liehn et al., 2011; Chatterjee and
Gawaz, 2013). Its role in atherosclerosis depends on the specific
environment, cell type and pathophysiological setting (Doring
et al., 2014).
Genome-wide-association studies discovered a relationship
of myocardial infarction with single nucleotide polymorphisms
(SNP) on chromosome 10q11 near the CXCL12 gene as a pow-
erful predictor for the susceptibility of coronary atherosclerosis
and myocardial infarction in association with higher CXCL12
plasma levels (Myocardial Infarction Genetics et al., 2009; Mehta
et al., 2011, 2013). Another study confirmed the same SNP
rs501120(T/T) to be associated with increased intima-media-
thickness and atherosclerosis but in contrast to Mehta et al. to
be associated with lower CXCL12 plasma levels (Kiechl et al.,
2010).
The systemic application of CXCL12 by injection into
apoE−/− mice mobilizes smooth muscle progenitor cells that
enter the vascular wall after partial ligation of the carotid
artery, leading to a more stable plaque phenotype (Akhtar et al.,
2013). This situation may be mimicked when platelets get acti-
vated and release substantial amounts of CXCL12. Moreover,
platelets express CXCR4 and CXCR7, which get upregulated
in patients with coronary artery disease. Therefore, platelets
maybe activated in an autocrine way as CXCL12 is a potent
platelet agonist abundantly expressed in atherosclerotic plaques
(Abi-Younes et al., 2000; Rath et al., 2014). Moreover, platelets
release CXCL12 after stimulation with thrombopoietin and sol-
uble c-kit ligand enhancing neovascularization by mobilization
of CXCR4+VEGFR1+ hemangiocytes in a model of hind limb
ischemia (Jin et al., 2006). Via the sympathetic nerve system and
the adrenoreceptor β3 the systemic effects of ischemia result in
a decrease of bone marrow derived CXCL12 and other reten-
tion factors. This triggers a subsequent release of circulating
progenitor cells that enhance the arterial infiltration of mono-
cytes and exacerbate atherosclerotic lesions, which could explain
why human atherosclerosis is accelerated after ischemic events
(Dutta et al., 2012). After activation by collagen or the adhesion to
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endothelial cells, human platelets release and present CXCL12 on
their surface. The presented CXCL12 activates CXCR4 on CD34+
progenitor cells, which leads to adhesion and to endothelial dif-
ferentiation (Stellos et al., 2008). The pathogenesis of neointima
formation shares several characteristics to atherogenesis. In the
area of arterial injury and endothelial denudation, platelets attach
readily to the intimal matrix proteins displaying CXCL12, P-
selectin and activated GPIIb/IIIa. This facilitates the subsequent
recruitment of bone marrow derived progenitors that aid in the
following reparative processes (Massberg et al., 2006).
In principle, with Plerixafor/AMD3100 an approved CXCR4
antagonist is available, which seems to be well-tolerated at least
for several months as tested in patients with a gain of func-
tion mutation in CXCR4 (WHIM syndrome) (Mcdermott et al.,
2014). Blocking CXCR4 inhibits the CXCL12-mediated reten-
tion in the bone marrow leading to a release of leukocytes and
progenitor cells. This renders CXCR4-antagonists useful to mobi-
lize and collect hematopoietic stem cells before autologous stem
cell transplantation. Blocking CXCR4 in murine vascular injury
models also reduced neointima formation (Karshovska et al.,
2008). In a murine model of atherosclerosis the inhibition of
the CXCR4-CXCL12 axis by AMD or transplantation of CXCR4
deficient bone marrow led to an increased number of circu-
lating leukocytes (predominantly neutrophils) correlating with
atherosclerotic lesions (Zernecke et al., 2008). Another receptor
for CXCL12 is CXCR7, now termed atypical chemokine receptor
3 (ACKR3) because it does not transduce signals via G-proteins
(Bachelerie et al., 2014). In humans CXCR7 has at least one
more ligand, CXCL11 which is naturally absent in C57/B6 mice.
Deletion of ACKR3/CXCR7 in apoE−/− mice results in increased
atherosclerotic lesion formation and the application of a small
molecule ACK3 agonist decreases atherosclerosis by a mechanism
that relates to the expression of ACK3 in white adipose tissue,
where it takes part in cholesterol metabolism (Li et al., 2014). How
platelet-derived CXCL12 affects specifically atherogenesis has yet
to be elucidated, e.g., by using models with a platelet-specific
CXCL12 deletion.
CXCL16
Together with CX3CL1, CXCL16 is the only chemokine that
contains a transmembrane domain which enables cell adhesion.
CXCL16 is an inflammation marker, expressed by numerous
cell types and is associated with atherosclerosis, and acute coro-
nary syndromes in humans (Lehrke et al., 2007). After cleav-
age it functions as a chemokine attracting T cells. Attached to
the cell membrane it is an adhesion receptor and endocytoses
oxidized lipoproteins. A constitutive CXCL16 knockout lead-
ing to decreased cholesterol efflux shows enhanced lesion size
attributable to protective scavenger receptor properties rather
than its chemokine functions (Aslanian and Charo, 2006; Barlic
et al., 2009). In contrast, CXCR6, the exclusive CXCL16 receptor,
has been described to promote atherosclerosis in a cell unspe-
cific CXCR6 knockout model by enhancing T-cell homing and
macrophage accumulation (Galkina et al., 2007). Both CXCR6
and CXCL16 are expressed by platelets and transduce PI3K/Akt
signaling leading to platelet activation and adhesion under high
shear stress (Borst et al., 2012). CXCL16 is upregulated upon
platelet activation and in acute coronary syndrome (Seizer et al.,
2011). Cell and platelet-specific models have not been used so far.
CXCL5
CXCL5 (LIX/ENA-78) plasma and tissue levels are increased dur-
ing atherogenesis in apoE−/− mice and CXCL5 seems to be
atheroprotective by enhancing the cholesterol efflux capacity of
macrophages and regulating foam cell formation (Rousselle et al.,
2013). The source of CXCL5 could potentially as well be platelets
that express CXCL5 at a high level (Karshovska et al., 2013).
MIF
The cytokine macrophage migration inhibitory factor (MIF) is
structurally and functionally related to the chemokine family
as it resembles the CXCL8-dimer and binds and activates CXC
chemokine receptors playing an aggravating role in atherogene-
sis (Bernhagen et al., 2007; Weber et al., 2008; Tillmann et al.,
2013). Platelets are a previously unrecognized source of MIF,
which is stored in α-granules but does not co-localize with
other chemokines or growth factors including VEGF. This may
explain the differential release upon ADP and oxLDL stimulation
compared to CXCL12 (Strussmann et al., 2013).
The release of chemokines from platelets is linked to platelet
activation, but depending on the individual chemokine, athero-
genic or protective effects occur (Figure 1). Proteins in α-granules
seem to be unequally distributed and numerous α-granule
cytokines and growth factors are not co-localized, which argues
for the possibility of a selective release. This issue has been
addresses by several studies but remains controversial (Italiano
et al., 2008; Kamykowski et al., 2011). It has been found that
platelet secretion follows a fast, medium, and slow rate and that
cargo release might be rather a stochastic process depending
on the structure or trafficking of the granule than a specifically
targeted process (Jonnalagadda et al., 2012).
Plasminogen activator inhibitor-1
PAI-1 excess promotes the development of intravascular throm-
bosis and atherosclerosis (Vaughan, 2005). Large amounts of
active PAI-1 are continuously produced by platelets (Brogren
et al., 2004). PAI-1 in mice affects atherosclerosis dependent on
the location. In the aortic arch the knockout or overexpression
in apoE−/− or LDLR−/− mice did not alter atheroprogression
(Sjoland et al., 2000). The same result was reproduced by a dif-
ferent group that additionally investigated atherosclerosis in the
carotid artery detecting a protection in PAI-1 knockout mice
(Eitzman et al., 2000). Consistent with the difference in atheroge-
nesis dependent from the arterial bed, fibrin deposition was more
intense in the carotid artery than in lesions of the aortic arch. PAI-
1 levels in humans correlate with IMT in diabetics (Adly et al.,
2014).
PLATELET ADHESION RECEPTORS AND CO-STIMULATORY
MOLECULES
GPIIb/IIIa AND GP1bα
Activated platelets have been documented to adhere to activated
endothelial cells in mouse models via surface expressed adhe-
sion molecules. The integrin GPIIb/IIIa (αIIbβ3) is a central
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FIGURE 1 | Effects of platelet-derived chemokines on inflammatory cells
and atherogenesis. Chemokines are stored in α-granules and secreted upon
activation. Most platelet-derived chemokines act on the one hand on
inflammatory cell differentiation and apoptosis. On the other hand, they act on
inflammatory cell adhesion to the endothelium with subsequent
transendothelial migration. Thus, platelet-derived chemokines are crucial
driving factors for atherogenesis. Further effects of platelet-derived chemokines
are the retention of bone-marrow leukocytes and regulation of lipid transport.
player in platelet adhesion and its absence in mice completely
prevents platelet adhesion to the carotid artery of apoE−/− mice
in vivo and the presence of an active von Willebrand Factor
(VWF)-receptor GP1bα is required to a large part, too. Blocking
or genetic deficiency of either one resulted in a considerable
reduction of atherosclerosis by reduced monocyte recruitment
(Massberg et al., 2002, 2005). A mechanistic aspect could be
that CXCL4 release by platelets was dependent on functional
GPIIb/IIIa in vitro (Zokai et al., 2001). Opposite to this find-
ing, the α- and dense granule release reaction of surface adherent
platelets was not GPIIb/IIIa dependent as shown with the block-
ing antibody fragment GPIIb/IIIa abciximab in experiments with
isolated human platelets (Ilveskero and Lassila, 2003). These
controversial effects of GPIIb/IIIa inhibitors on platelet gran-
ule release are possibly due to the fact that mediators activating
platelets cause both, aggregation through inside-out signaling of
GPIIb/IIIa and secretion via an alternative pathway. In the latter
case, outside-in signaling of the integrin is not required leading to
the notion that GPIIb/IIIa inhibition results in a dissociation of
the aggregatory and secretory response (Tsao et al., 1997; Ogawa
et al., 2002; Naimushin and Mazurov, 2003).
Conflicting results exist in addition whether GPIIb/IIIa
inhibitors are able to reduce the formation of atherogenic platelet-
leukocyte complexes (Klinkhardt et al., 2002).
These experimental conditions are mimicked in patients with
inherited platelet disorders such as Glanzmann thrombasthe-
nia (GPIIb/IIIa), Bernard Soulier Syndrome (GPIbα) and von
Willebrand disease (VWD). From studies of Glanzmann patients
we know that the absence of GPIIb/IIIa does not fully pro-
tect from atherosclerosis since ultrasound of the carotid bifur-
cation revealed plaques in 4 of 7 patients (Shpilberg et al.,
2002). Therefore, platelet-vessel wall interactions via GPIIb/IIIa
seem not to be required in human atherosclerosis and may be
replaced functionally by other platelet receptors. Orally admin-
istered GPIIb or GPIIIa inhibitors would be of use to conclude
on this question but have been abandoned due to increased mor-
tality and exist only as i.v. drugs. The reason for the increased
mortality in phase III trials with oral GPIIb/IIIa antagonists has
not been elucidated and pharmacokinetics rather than the mech-
anism itself may be blamed so that the quest for appropriate
antagonists continues (Bledzka et al., 2013). Junctional molecules
altering GPIIb/IIIa activity are additional potential therapeutic
candidates. For instance, JAM-A (junctional adhesion molecule
A), a member of the superimmunoglobulin class of adhesion
molecules is expressed by platelets. Surprisingly, JAM-A defi-
ciency leads to an increase of GPIIb/IIIa-mediated outside-in
signaling (Naik et al., 2012).
VWF
Not much is known about the relevance of human VWF and
its receptor complex for atherosclerosis. In a rabbit model of
atherosclerosis, it was shown that endothelial VWF recruited
platelets to atherosclerosis-prone sites in response to hypercholes-
terolemia (Theilmeier et al., 2002). The complete absence of VWF
in humans (VWD type 3) seems not to protect from atheroscle-
rosis as a study with relatively young individuals (average 37
years) suggested. Healthy controls and patients were examined by
ultrasound and showed a comparable percentage of plaques and
Intima-Media-Thickness (Sramek et al., 2004).
P-SELECTIN
P-selectin is upregulated on endothelial cells and platelets upon
activation and mediates platelet and leukocyte rolling on the
endothelium. Activated platelets rapidly release P-selectin by
shedding but continue to circulate and function (Michelson
et al., 1996). Platelets express the fractalkine (CX3CL1) receptor
CX3CR1 and get activated by inflamed endothelial cells through
their surface displayed CX3CL1 triggering P-selectin exposure
on adherent platelets, which thereby initiates the local accumu-
lation of leukocytes under arterial shear (Schulz et al., 2007).
Increased soluble P-selectin levels of apparently healthy women
predict future vascular events (Ridker et al., 2001). High lev-
els of P-selectin on platelets are associated with an increased
Intima-Media-Thickness (Koyama et al., 2003). In amousemodel
of atherosclerosis, investigating the promotion of atherosclerosis
by an adoptive transfer of P-selectin positive or negative bone
marrow platelets, in addition to endothelial P-selectin, platelet
P-selectin contributed to lesion formation (Burger and Wagner,
2003). Platelet P-selectin supports the recruitment of monocytes
and other leukocytes by aiding the formation of platelet-leukocyte
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complexes and facilitating the deposition of inflammatory platelet
mediators on endothelial cells (Schober et al., 2002; Huo et al.,
2003). A novel oral non-peptide inhibitor of P-selectin failed
to decrease the formation of monocyte-platelet aggregates (Japp
et al., 2013). A P-selectin blocking monoclonal antibody has been
tested in NSTEMI patients, but had only a small but positive effect
onmyocardial necrosis and is planned to be applied in the chronic
setting of atherosclerotic peripheral artery disease (Tardif et al.,
2013) (NCT00760565).
THE CD40-CD40L DYADE
CD40 ligand (CD154, CD40L) is a transmembrane protein of
the TNF-family and one of the best characterized co-stimulatory
molecules. CD40L activates CD40 thereby stimulating athero-
genic immune responses (Lievens et al., 2009). CD40 and CD40L
are expressed by numerous cell types, but in the circulation
CD40L is mainly derived as cleavage product from activated
platelets (Henn et al., 1998). Whole body deficiency of CD40L
or of hematopoietic CD40 reduces atherosclerotic lesion size and
induces a stable plaque phenotype through signaling of the intra-
cellular adaptor TRAF6 but not TRAF2/3/5 (Lutgens et al., 1999,
2010). Platelet CD40L interaction with endothelial cells induces
the release or upregulation of chemokines (e.g., CCL2 and CCL5),
adhesion molecules (e.g., ICAM-1, VCAM-1), metalloproteases
(e.g., MMP-1, -2, -3, and -9) and tissue factor supporting
platelet-endothelium interaction, but also leukocyte recruit-
ment via the formation of platelet-leukocyte-aggregates (Lievens
and Von Hundelshausen, 2011). Atherosclerotic lesion forma-
tion was increased if activated wild type platelets were injected
into apoE−/− mice compared to CD40L-deficient platelets. The
responsible mechanisms comprised less platelet leukocyte aggre-
gates and no depletion of T-regs by CD40L deficient platelets
(Lievens et al., 2010). Vice versa, CD40L-positive T cells activate
platelets through a CD40-dependent pathway resulting in CCL5
release and T cell recruitment (Danese et al., 2004). Furthermore,
ligation of platelet CD40 with a recombinant soluble CD40L aug-
ments P-selectin expression, α-granule and dense granule release
and the typical shape change that is associated with platelet acti-
vation. Some atherogenic effects of CD40L are not mediated by
CD40 but are explained by the interaction with the I-domain of
the integrin MAC-1 that can be blocked by peptide inhibitors
(Wolf et al., 2011). Anti-CD40L treatment in patients with sys-
temic lupus erythematodes led to an increase of thrombotic
events that are assumed to depend on the Fc part of the anti-
body, which activates platelets via their Fc-receptor gamma. This
could be principally overcome by engineering an inert Fc-part
(Sidiropoulos and Boumpas, 2004; Xie et al., 2014). However,
the desired immunosuppressive effects of a long-term inhibition
are not acceptable in cardiovascular prevention. A resort can be
the mentioned selective antagonism of TRAF6 that blocks only
the atherogenic pathway of CD40L-CD40 signaling being enabled
by the distinct binding site to TRAF1/2/3/5. Controversially,
platelet CD40L might have as well anti-inflammatory properties
related to the interaction between CD40L and CD40, and exert a
hitherto undescribed immunoregulatory action by enhancing IL-
10 production and inhibiting TNF-α production by monocytes
(Gudbrandsdottir et al., 2013).
PLATELET-DERIVED MICROPARTICLES IN
ATHEROSCLEROSIS
Platelet-derived microparticles (PMP) are small phospholipid-
vesicles loaded with bioactive substances being shed from aged
or activated platelets (Heemskerk et al., 1997). There is growing
evidence for PMP playing important roles in atherosclerosis (Tan
and Lip, 2005). In healthy subjects, low numbers of PMPs circu-
lating in the blood exert only minor effects like phospatidylserine
catalyzed generation of negligible amounts of thrombin (Rautou
et al., 2011), but upon activation PMP abundance in the blood
rises, as suggested by ex vivo activation with TRAP and ADP
of platelets from convalescent stroke patients (Lukasik et al.,
2013). PMPs were identified as transcellular delivery systems for
chemokines such as CCL5 promoting monocyte recruitment and
atherosclerosis (Mause et al., 2005). Moreover, PMPs were shown
to interact with monocytic MM6 cells subsequently inducing
integrin (α5), interleukin (IL-1β, -7, -11) and CCL5 expression
(Setzer et al., 2006). Besides augmented monocyte recruitment,
enhanced adherence of murine progenitor cells to sites of wire-
induced arterial injury had been demonstrated to be mediated by
PMPs pointing toward an additional regenerative role for PMP
(Mause et al., 2010). Taken together, these data provide strong
evidence for a contribution of PMPs in atherosclerotic lesion
formation.
ROLE OF PLATELETS IN CHOLESTEROL ACCUMULATION
A detailed review covering the major aspects of the interplay of
platelets with native and modified lipoproteins summarizing the
contribution of platelets to foam cell formation in atherosclerosis
has been published elsewhere (Siegel-Axel et al., 2008).
Platelets bind, modify and endocytose LDL particles as an
early in vitro study demonstrated by adding activated platelets
to smooth muscle cells or macrophages. This induces the for-
mation of intracellular cholesterol ester droplets independent on
extracellular lipids and intracellular cholesterol synthesis, which
were not observed with resting platelets (Kruth, 1985). Platelets
express several receptors for lipoproteins: CD36 (SR-BIII), SR-
BI, SR-BII, LOX-1, apoE Receptor 2 and CXCL16 that contribute
in these processes. In line with the atherogenic role of blood-
borne LDL and the protective role of HDL, LDL, and oxLDL
proteins activate platelets in contrast to HDL, which through
binding to SR-BI exerts an indirect influence on platelet reactiv-
ity via maintaining normal plasma cholesterol homeostasis and
generates an inhibitory signal for platelet activation (Korporaal
et al., 2011; Nofer and Van Eck, 2011). Lowering LDL cholesterol
by statins or lipid apharesis led to a decrease in the MPV (Blaha
et al., 2013; Sivri et al., 2013). Stimulation of platelets with oxLDL
resulted in the formation of platelet-monocyte-aggregates (PMA)
and phagocytosis of platelets in whole blood and increased oxLDL
uptake by monocytes, which was dependent on platelet CD36
and the release of CXCL4 (Badrnya et al., 2014). Interestingly,
the same study reported that platelet inhibition by aspirin or
clopidogrel was effective in preventing oxLDL uptake and PMA
formation, attributing cardiovascular beneficial effects of aspirin
and clopidogrel to these mechanisms.
Hypercholesterolemia increases the number of circulating
neutrophils and monocytes but as well the platelet count
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by enhanced production via the cholesterol-efflux transporter
ABCG4 on megakaryocyte progenitors, which in turn affects
cholesterol-sensing LYN- kinase and signaling of the thrombopoi-
etin receptor c-mpl (Murphy et al., 2013).
MECHANISMS OF PLATELET-MEDIATED ATHEROGENESIS
GET APPARENT BY CARDIOVASCULAR DRUGS
Linking inflammation and thrombosis supports the hypothesis
that agents with both anti-inflammatory and antiplatelet effects
may reduce vascular inflammation and limit acute and long-term
thrombotic events.
P2Y12R ANTAGONISTS
Inflammation, cell death and activation lead to the release of
nucleotides such as ATP and ADP by various cell types includ-
ing platelets binding and activating purinergic receptors. Platelets
express the ADP receptors P2Y12 (Gi linked) and P2Y1 associ-
ating with Gq as well as the ATP activated ion channel P2X1.
P2Y1 signaling activates phospholipase C, which will be fol-
lowed by platelet shape change, whereas activation of the P2Y12R
triggers platelet aggregation via GPIIb/IIIa and is the target of
well-established antagonists such as clopidogrel, prasugrel, and
ticagrelor that are applied in the prevention of arterial thrombosis
(Idzko et al., 2014). Given the importance of nucleotide signaling
in inflammation and the concept of platelets being inflamma-
tory cells with immunologic tasks, P2Y12R should play a role in
platelet-mediated inflammation and atherosclerosis.
Indeed, P2Y12R deficient mice are partially protected from
atherosclerosis by a reduction of α-granule release leading to a
lower P-selectin expression and lower plasma levels of CXCL4 (Li
et al., 2012). Similar to diet-induced atherosclerosis, transplant-
associated atherosclerosis features arterial leukocyte infiltration.
In P2Y12R deficient mice platelets expressed lower levels of
CD40L and formed fewer aggregates with leukocytes additional
to mediating lower adhesion molecule levels in endothelial cells
(Yashiro et al., 2009). The use of P2Y12R antagonists in animals
brought conflicting results. Ticlopidine, a first generation P2Y12
inhibitor, and clopidogrel showed atheroprotective effects (Jawien
et al., 2007; Afek et al., 2009), which could not be reproduced in
another study using clopidogrel, aspirin or a combination thereof
(Schulz et al., 2008).
Adding clopidogrel to aspirin in the CHARISMA trial in stable
CAD patients did not improve outcome or reduce cardiovascu-
lar events over 2 years thus failing to translate the positive results
of the CAPRIE trial into primary prevention that were obtained
in the setting of AMI (Chen et al., 2005; Bhatt et al., 2006). The
reasons for the failure of clopidogrel to reduce atherosclerosis
in humans despite the positive preclinical data are unclear but
without understanding the cause it will be difficult to encour-
age additional clinical trials addressing the clinical efficacy of
other P2Y12R antagonists (such as prasugrel or ticagrelor) for the
treatment or prevention of chronic inflammation and its compli-
cations. Whether long-term clopidogrel treatment (12 months)
had an influence on inflammation and whether the effects were
stable over time was investigated in the ELAPSE trial (Saw et al.,
2008). During 12 months follow-up the C-reactive protein lev-
els of 26 CAD patients remained constant while IL-18 levels
increased significantly although platelet function testing did not
show a decline in inhibition of aggregation through clopido-
grel. After 1 year the surface expression of P-selectin and CD40L,
but not activated GPIIb/IIIa was elevated, leading to the con-
clusion that clopidogrel and maybe in general P2Y12 inhibitors,
although still blocking aggregation, could lead to platelet activa-
tion and have general inflammatory side effects. It is expected
that effective platelet inhibition would most likely lead to lesser
chemokine secretion and adhesion molecule expression as exem-
plarily shown in plasma of patients with type 2 diabetes mellitus,
where CCL5- and P-selectin-levels are decreased (Harding et al.,
2006).
THROMBIN AND THROMBIN RECEPTOR ANTAGONISTS
A role of the serine protease thrombin for the initiation of
atherosclerosis is testified by the presence of thrombin-generating
activity in early atherosclerotic lesions and increased atheroscle-
rosis in mice (Iwaki et al., 2006; Borissoff et al., 2011). Thrombin
generated at sites of vascular inflammation activates major
atheroma-associated cells including endothelial cells, platelets,
smooth muscle cells, monocytes, and macrophages producing
a wealth of inflammatory mediators and procoagulant activity
resulting in a positive feedback loop (Croce and Libby, 2007).
Multiple substrates of thrombin binding to exosite I or II are
relevant for its biological activity including the activation of pro-
teinase activated receptors 1 and 4, binding to GPIbα as well
as the cleavage of several coagulation factors (fibrinogen, XI, V,
VIII), which make thrombin an important player linking throm-
bosis and innate immunity (Lane et al., 2005; Engelmann and
Massberg, 2013). Importantly, low concentrations of thrombin
are thought to have antithrombotic and inflammatory properties
as low concentrations of thrombin are complexed on endothelial
cells with protein C, thrombomodulin and the endothelial protein
C receptor (EPCR) generating activated protein C thus attenuat-
ing the effects of thrombin on coagulation by cleaving FV andVIII
as well as transducing anti-inflammatory signals via endothelial
PAR-1 (Riewald et al., 2002; Kalz et al., 2014). At higher concen-
trations thrombin specifically activates platelets through human
PAR-1 and PAR-4 corresponding to mouse PAR-4 and PAR-3,
respectively, whereas murine PAR-1 is not relevant for platelet
activation (Kahn et al., 1998; Major et al., 2003). Human PAR-1 is
the high affinity thrombin receptor resulting in a fast and short
activation, whereas PAR-4 has a low apparent affinity, but due
to its prolonged activation it dominates the signaling over time
despite its slow activation rate (Covic et al., 2000).
DIRECT THROMBIN INHIBITORS
The repertoire of oral anticoagulants has been extended by Factor
Xa antagonists and the direct thrombin inhibitor dabigatran
which reduces atherogenesis in mouse models. Heterozygeous
prothrombin deficient mice or blocking thrombin with dabiga-
tran reduces the size of atherosclerotic lesions in mice and at the
same time increases plaque stability through effects on MMPs,
endothelial dysfunction and neutrophil recruitment (Kadoglou
et al., 2012; Borissoff et al., 2013; Pingel et al., 2014).
These models provide the insight that targeting thrombin
activity may be beneficial, but due to the multifaceted effects of
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thrombin affecting multiple cell types and plasmatic proteins the
answer which cell type contributes most to thrombin-dependent
atherogenesis remains open. In the setting of secondary prophy-
laxis where aspirin and often clopidogrel are co-administered
caution is needed before adding another therapy affecting
hemostasis.
THROMBIN RECEPTOR ANTAGONISTS
The same holds true for the inhibition of thrombin receptors.
Here, tissue specific animal models are feasible. Presently, four
members of the PAR family have been cloned and identified.
Human platelets express and are activated via PAR-1 and PAR-4 to
release substantial amounts of cytokines and chemokines which
modulate atherosclerosis (see above). The development of PAR
knockout mice has provided the unique opportunity to identify
and characterize the members of this family of GPCRs, to eval-
uate the interaction of PARs jointly expressed in common cells
and tissues, and better understand the role of PARs in thrombosis,
restenosis, vascular remodeling, angiogenesis, and inflammation
(Major et al., 2003).
Surprisingly, the deficiency in the major murine platelet
thrombin receptor PAR-4 seems not to be atheroprotective in
apoE−/− mice, at least at the early stages at 5 and 10 weeks on
Western diet, although platelet activation by thrombin was abol-
ished (Hamilton et al., 2009). As PAR-4 is expressed by various
other cell types, a compensating effect might be the explana-
tion or relates to the finding that PAR signaling is important for
platelet activation and clot formation, but not for the formation
of the initial platelet monolayer at sites of injury (Vandendries
et al., 2007; Angiolillo et al., 2010). PAR-1 antagonists have there-
fore been proposed to tackle platelet-mediated thrombosis rather
than platelet hemostasis (Angiolillo et al., 2010).
The two selective and reversible PAR-1 antagonists in most
advanced clinical development are vorapaxar and atopaxar. The
latter has been studied in the phase II LANCELOT trials. The
LANCELOT-ACS trial compared placebo and different doses of
atopaxar on top of the standard therapy with aspirin and clopi-
dogrel in 603 patients presenting with non-ST-elevation ACS, but
failed to demonstrate a difference in hard endpoints.
While ischemic events, as determined by the surrogate param-
eter continuous ECG monitoring, significantly favored atopaxar,
neither hard endpoints nor the incidence of bleedings differed sig-
nificantly. The treatment of CAD patients with atoxapar did not
result in a reduction of inflammatory mediators, at best soluble
CD40L decreased (O’donoghue et al., 2012). Another selective
PAR-1 antagonist, vorapaxar, has been shown to be safe and
well-tolerated in phase I and II studies but was terminated early
in a phase III trial treating ACS patients (TRACER) because of
increased bleeding compared to not-significantly lower cardio-
vascular events (Tricoci et al., 2012). In secondary prevention
(TRA 2P-TIMI 50) vorapaxar proved to be effective (Morrow
et al., 2012) but this benefit was abolished by moderate to severe
bleeding, including intracranial hemorrhage.
The concept of thrombin receptors as targets to treat and
prevent atherosclerotic complications has partially proven effec-
tive but could not solve the dilemma of anti-platelet therapies.
However, the receptor PAR-4 could be a potential candidate.
HEPARIN
Unfractionated heparin, a family member of the glycosamino-
glycans, has been used for decades as a standard anticoagulant
in cardiovascular diseases inhibiting thrombin by binding to and
increasing the effectivity of antithrombin III (AT). Beyond anti-
coagulation, heparin and its variants play a role in atherosclerosis,
preferably adhering at the endothelial cell lining and inhibiting
platelet endothelial cell interactions, preventing lipid uptake, and
increasing lipoprotein-lipase A2 activity (Engelberg, 1980). As
conventional heparin has to be applied parenterally and longer
courses are regularly complicated by CXCL4-heparin complexes
provoking heparin-induced thrombocytopenia (HIT), only short
term applications are practical and seem to contradict a realis-
tic perspective of heparin as treatment option for the chronic
disease atherosclerosis. However, short term heparin application
may alter the prognosis during acute ischemia, which is an impor-
tant driver of atherosclerosis by enhancing the pool and num-
ber of circulating monocytes and progenitor cells via CXCL12
(Dutta et al., 2012). It is known that administration of hep-
arin results in a moderate increase in the white blood cell count.
Many activities of heparin, mainly by binding to growth-factors
and chemokines may be important to understand completely as
they mediate the mobilization and recruitment of cells affecting
atherosclerosis (Xu and Dai, 2010). Heparin-induced leukocyto-
sis affects less than 1% of patients, requires 6-O-sulfation and is
caused by blockade of selectin- and CXCL12-mediated leukocyte
trafficking in mice (Zhang et al., 2012). Heparin oligosaccha-
rides inhibit CXCL12 by orthogonally binding to the dimeriza-
tion interface, promoting oligomerization, and competing with
CXCR4, which prevents progenitor cell recruitment (Ziarek et al.,
2013).
Patients with atherosclerosis have low intraplatelet stores of
CXCL4, but large extracellular deposits reflecting chronic platelet
activation and release. Administration of heparin in these patients
mobilizes larger amounts of CXCL4 into the circulation than in
healthy individuals (O’brien et al., 1984). In terms of antithrom-
botic activity heparin neutralizes CXCL4 and possibly other
activities of the chemokine (Eslin et al., 2004).
The heparin binding motif in CCL5 in the 40s loop is
important for its biological activity and contributes to atheroscle-
rosis. Injecting a CCL5 mutant [44AANA47]-RANTES in LDLR-
deficient mice protects from atherosclerosis (Braunersreuther
et al., 2008). Designing heparin oligosaccharides may therefore
help to selectively modulate chemokine activity (De Paz et al.,
2007).
Summing up, heparin might exert beneficial effects on
atherosclerotic lesion formation by blocking CXCL12 and
CXCL4, but the induction of atherogenic leukocytosis might
counter-balance these positive effects and additionally impede
healing processes after myocardial infarction.
CYCLOOXYGENASE-1 INHIBITORS
Aspirin (acetylsalicyl acid, ASA) is the standard drug in the sec-
ondary prevention of myocardial infarction and stroke. It acts
in the usually applied low doses as an irreversible inhibitor of
cyclooxygenase (COX-1), an enzyme required for the synthesis of
prostaglandins such as thromboxane A2, which mediates platelet
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thromboxane receptor amplifying platelet aggregation (Coccheri,
2010).
Other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
failed to show a protective effect on myocardial infarction, which
might be due to inhibiting cyclooxygenase reversibly in con-
trast to the irreversible binding of aspirin (Ray et al., 2002).
Numerous large-scale clinical trials and meta-analyses have con-
sistently demonstrated the benefit of low doses of aspirin as a
secondary prevention measure for recurrent ischemic events in
patients with various manifestations of atherothrombotic disease,
whereas the effect in primary prevention is small and doubtful
(Baigent et al., 2009). In the largest previous placebo-controlled
trial of antiplatelet therapy for secondary prevention in patients
with stable atherothrombosis or at high risk for vascular disease,
clopidogrel plus aspirin was no better than aspirin alone in the
overall cohort (Bhatt et al., 2006).
In contrast, experimental studies demonstrated that aspirin
is atheroprotective (Paul et al., 2000; Cyrus et al., 2002; Tous
et al., 2004). The exposition of isolated human platelets to various
platelet agonists results in a differential profile of released platelet
proteins, attenuated by aspirin irrespective of which agonist was
used (Coppinger et al., 2007). Additionally, both clopidogrel and
aspirin were shown to decrease atherosclerosis in rabbits and at
the same time reducing P-selectin and thus platelet adhesiveness,
as well as MCP-1 expression (Li et al., 2007b).
The lack in efficacy of aspirin and clopidogrel in primary pre-
vention is in striking contrast to the in vitro and in vivo studies
describing an atherogenic role of COX-1-mediated platelet acti-
vation leading to an enhanced release of inflammatory mediators
and cellular recruitment and the development and progression of
atherosclerotic lesions in hyperlipidemic mice and rabbits.
STATINS
Research into fungi and cholesterol led to the development of
statins (Endo et al., 1976), which inhibit the 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG-CoA reductase) which is the first
and key enzyme of cholesterol biosynthesis (Figure 2: statins:
mechanisms of action), thereby preventing the generation of
cholesterol precursors in the liver and reducing LDL-cholesterol,
the pivotal cardiovascular risk factor. Cholesterol lowering statins
are one of the most commonly used classes of atheroprotective
drugs and so far exclusively proven to be beneficial in the pri-
mary prevention of myocardial infarction and stroke (Robinson,
2013). In clinical trials some of the protective properties of statins
were not correlated with the reduction in cholesterol levels. At
present it is unclear whether and to what extent LDL reduc-
tion or other modes of actions are responsible for the improved
cardiovascular outcome in high risk patients. Anti-thrombotic,
anti-inflammatory, endothelium protective, and plaque stabiliz-
ing properties are additional attributes of statins and outline the
so-called pleiotropic, cholesterol independent, effects (Lefer et al.,
2001; Liao and Laufs, 2005; Violi et al., 2013).
The clinical relevance of the antithrombotic effects of statins
remains controversial. High-dose atorvastatin in the SPARCL
trial (Stroke Prevention by Aggressive Reduction in Cholesterol
Levels), decreased the overall rate of recurrent ischemic events in
patients with stroke and were overall protective at the expense of
increased intracranial hemorrhage (Amarenco et al., 2006). Later,
smaller observational cohorts and a meta-analysis however were
not confirmative (Biffi et al., 2011). Scientifically, it will be dif-
ficult to clearly separate the off- and on-target effects of statins.
Moreover, the issue of antithrombotic effects of statins has not
been addressed directly by randomized trials.
Nevertheless, antithrombotic pleiotropic properties may be
inferred from acute clinical effects when statins not yet have
reduced plasma cholesterol. A meta-analysis summarizing the
data of 13 studies testing short term, high-dose statins, started just
before PCI, demonstrated both a large relative reduction of 44%
of periprocedural myocardial infarction irrespective of the clinical
setting (ADP antagonist, acute event, etc.) and later a reduction
in adverse cardiac events. Due to the short time frame a lipid
lowering effect was not yet effective, implying pleiotropic effects
(Patti et al., 2011). The PRISM trial (Platelet Receptor Inhibition
in Ischemic Syndrome Management) demonstrated a better out-
come of ACS patients when they were on statins in the first month
after the event, which is unlikely to be caused by remodeling pro-
cesses of the plaque in such a short timeframe and are rather to be
explained by reduced platelet activation and/or attenuated coagu-
lation system. It was observed that statins have an early inhibitory
effect on platelets of patients with AMI showing reduced aggre-
gation after challenge with collagen and a markedly lower platelet
surface adhesion in vitro (Matetzky et al., 2011).
Statins may exert effects on atherosclerotic lesion forma-
tion via decreasing long-term platelet activation and platelet-
chemokine secretion by various mechanisms. Platelets release
nitric oxide (NO) upon activation preventing in a negative feed-
back loop further platelet activation and recruitment (Freedman
et al., 1997). NO is generated in platelets by eNOS (endothelial
type III nitric oxygen synthase) utilizing arginine as substrate.
Statin treatment leads to an upregulation of eNOS, decreases
platelet activation, lowers plasma levels of the platelet chemokines
CXCL4 and CXCL7 in vivo and protects from cerebral ischemia
in normocholesterolemic mice (Laufs et al., 2000). On the other
hand, O2 radicals will deplete NO. Atorvastatin decreases acutely
and simultaneously oxidative stress and platelet activation by
directly inhibiting platelet Nox2 (NADPHoxidase) and ultimately
platelet isoprostanes and thromboxane (Pignatelli et al., 2012).
Therefore, statins may reduce oxidized LDL by lowering LDL and
oxidative stress increasing NO availability at the same time. The
molecular details, i.e., where exactly statins bind to the enzymes
are not yet determined.
Beyond eNOS-dependent effects of statins, animal studies
demonstrated additional mechanisms such as inhibiting signal-
ing of the thrombin receptor PAR-4 (Ni et al., 2012). Small
GTPases such as Rho, Ras, and Rac play a central role in the
signaling and cytoskeletal rearrangements required for platelet
activation (Aslan and Mccarty, 2013). RhoA activates GTP-
bound ROCK (Rho-associated coiled-coil containing protein
kinase), which in turn activates MLC (myosin light chain) and
is necessary for the contraction of actin fibers. The intracellular
location of Rho-GTPases is dependent on isoprenoid interme-
diates. Hence, the reduced activity of ROCK in patients with
high dose simvastatin is biologically plausible (Liu et al., 2009).
Despite the implications of statins as anti-platelet agents, their
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FIGURE 2 | Effects of platelet-derived chemokines on inflammatory cells
and atherogenesis. Chemokines are stored in α-granules and secreted upon
activation. Most platelet-derived chemokines act on the one hand on
inflammatory cell differentiation and apoptosis. On the other hand, they act on
inflammatory cell adhesion to the endothelium with subsequent
transendothelial migration. Thus, platelet-derived chemokines are crucial
driving factors for atherogenesis. Further effects of platelet-derived chemokines
are the retention of bone-marrow leukocytes and regulation of lipid transport.
role for the signaling of small GTPases and the above men-
tioned mechanisms still need further clarification. The suppos-
edly general effect on small GTPases might be responsible for
the statin-mediated blockade of junctional adhesion molecule
A (JAM-A) re-localization on endothelial cells under athero-
genic conditions, including low shear stress and hyperlipidemia.
Under resting conditions, JAM-A is evenly distributed at endothe-
lial cell-cell interfaces, whereas it appears to be redistributed
profusely under atherogenic conditions. The junctional local-
ization of JAM-A could be restored upon challenging with a
statin likely facilitated by reducing actin stress-fiber formation
(Schmitt et al., 2014). Furthermore, high-dose (>5μM) atorvas-
tatin redistributed proteins, including chemokines, intracellularly
to CD63 positive platelet and endothelial multivesicular bodies
which was associated with a lower secretion (Hol et al., 2012). The
presentation of chemokines on endothelial cells and endothelial
JAM-A re-localization through exposure with oxidized low den-
sity lipoprotein (LDL) or cytokines was an important prerequisite
for the transendothelial migration of inflammatory leukocytes
(Jaczewska et al., 2014). Therefore, reducing hot spots of apical
JAM-A and chemokine accumulation for migration may mitigate
leukocyte infiltration.
Using an atherosclerosis model in rabbits, Li and col-
leagues furthermore found an association between the reduc-
tion in atherosclerotic lesions induced by statins as well as by
aspirin or clopidogrel and the reduction of soluble P-selectin.
Interestingly, atorvastatin showed a comparable reduction in
plasma sP-selectin to clopidogrel treated animals which might be
a platelet-dependent effect (Li et al., 2007a). P-selectin on platelets
was diminished by 20% after 8 weeks when fluvastatin (40mg)
was compared with placebo (Huhle et al., 1999). Well-correlating
levels of sP-selectin and IL-1β in 50 patients at baseline and a
comparable decline after 8 weeks of treatment with either sim-
vastatin (20mg) or aspirin (100mg) brought the perception that
platelet activation (sP-selectin) in hypercholesterolemia correlates
with inflammation (IL-1β) and that both, simvastatin and aspirin
lower platelet activation to the same extent but surprisingly only
simvastatin lowered the inflammation marker CRP. As baseline
was compared with solely 8 weeks of treatment, the differentia-
tion in cholesterol-dependent and -independent effects was not
feasible (Ferroni et al., 2003).
Studies on patients with hypercholesterolemia demonstrated
on the other hand a statin-mediated decrease in platelet expressed
and plasmatic soluble CD40 ligand that correlated with choles-
terol levels, arguing against an exclusive pleiotropic mechanism
and favoring the concept that high concentrations of cholesterol,
lipoproteins and its oxidized modifications (oxLDL, mmLDL)
activate platelets (Cipollone et al., 2002; Semb et al., 2003;
Sanguigni et al., 2005; Undas et al., 2005).
A further, recently discovered molecular mechanism of statin-
mediated pleiotropic platelet inhibition regards the platelet
molecule PECAM-1. Fluvastatin and simvastatin were found
to reduce acute platelet aggregation, dense granule release and
thrombus growth in vitro and in animal models by activating
the signaling of PECAM-1, an inhibitory platelet membrane pro-
tein. Adding these statins to platelets reduced collagen-induced
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platelet activation, stimulated the phosphorylation of PECAM-
1, which increased the activity of the phosphatase SHP-2, and
subsequently diminished PI3K and AKT signaling (Moraes et al.,
2013). However, the immediate mechanism leading to PECAM-1
phosphorylation remained still concealed. An important indirect
AKT inhibitor is the phosphatase PTEN (phosphatase and tensin
homolog) that dephosphorylates upstream IP3, the product of
PI3K, which plays a role in platelet activation and reduces the
number of circulating platelets by attenuating megakaryopoiesis
(Weng et al., 2010; Kauskot et al., 2013). An increased expres-
sion of PTEN through statins might be operable either by an
enhanced translation in the platelet or reduced suppression in
megakaryocytes by NfkappaB. Simvastatin inhibits the binding of
NfkappaB to the recognition sites NRF1/2 in the PTEN promotor
(Ghosh-Choudhury et al., 2010). Moreover, statins inhibit even
at low concentrations in vitro NfkappaB by activation of ERK5
(extracellular-signal-regulated kinase 5=MAP3Kinase7), which is
well-expressed in platelets (Burkhart et al., 2012; Wu et al., 2013).
Taken together, a variety of studies demonstrated direct or
indirect effects of statins on platelet activation, subsequently lead-
ing to a reduced expression and secretion of pro-inflammatory
chemokines, cytokines as well as inflammatory molecules such
as P-selectin and soluble CD40 ligand on this way affecting
atherosclerotic lesion formation. For the clinician and the deci-
sion making the way statins exert their beneficial effects in car-
diovascular patients may be of secondary importance. As a tool
to understand why statins protect from atherosclerosis they aid in
identifying multiple targets for future interventions. A limitation
in the translation of in vitro studies to the clinical situation is that
the observed effects of statins were mostly elicited at micromolar
concentrations, more than orders of magnitude higher than what
can be achieved even with high oral statin doses.
Maybe indeed the anti-platelet and other pleiotropic effects
are of greater importance than estimated if we consider the
missing evidence for cardiovascular survival of other cholesterol
reducing agents such as ezetimibe and fibrates. Ezetimibe low-
ers LDL cholesterol by inhibiting the intestinal resorption and
fibrates reduce LDL cholesterol by enhancing the catabolic activ-
ity via PPARα. The effect sizes of both agents on LDL are smaller
compared with statins. Whether the antithrombotic and anti-
inflammatory effects of statins are results of the inhibition of a
concomitant off-target effect reducing isoprenoids might be tack-
led when PCSK9-inhibitors, a promising new class of strong LDL-
reducing agents that do not affect the substrates of HMG-CoA,
will be scrutinized.
CONCLUSION
Our current assessment of the role of platelets for atherogensis
is vastly driven by the insights gleaned from animal models of
atherosclerosis that allow to study the role of single molecules
in a cell and tissue specific manner by using conditional tar-
geted genes. Commonly platelet specific expression or deletion
is achieved using the CXCL4 promotor (PF4-Cre). The answers
that can be obtained are as good as the models of atheroscle-
rosis that are available, typically apoE- or LDLR- deficient mice
put on cholesterol rich diet, which copy some but not all of the
characteristics of human atherosclerosis. We have to acknowledge
that our understanding of human atherogenesis is still very lim-
ited, which is in part due to the technical difficulty in assessing
reliably, non-invasively and with reasonable efforts the atheroscle-
rotic burden over time in humans leading to the employment
of sometimes weak surrogate parameters such as Intima-Media
thickness and soft end points. Hard endpoints, however, do not
tell us whether beneficial effects by antiplatelet drugs on cardio-
vascular mortality, stroke and myocardial infarction derive from
fewer plaque ruptures due to alterations in the size and stabil-
ity of atherosclerotic lesions or rather from mere thrombotic and
hemostatic inhibition. Examples are the oral GPIIb/IIIa antag-
onists that failed to keep their promises or the side effects of
PAR-1 antagonists demonstrating the difficulty to separate clearly
antithrombotic and anti-inflammatory properties from antihe-
mostatic effects. An increase in understanding and dissecting the
specific role of platelets in atherosclerosis compared to thrombo-
sis has to be envisioned to result in novel anti-platelet targets and
therapies, which are clearly needed to improve the prevention of
atherosclerotic complications.
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